News ReleaseView printer-friendly version
Quidel Expands Influenza Testing in European Community; German School System and French Soccer Team Adopt the QuickVue(R) Influenza A+B Test
SAN DIEGO, Feb 21, 2006 (BUSINESS WIRE) -- Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today, the adoption of the QuickVue Influenza A+B test in an Influenza Prevention Program for students enrolled at all Nymphenburger Schools throughout Munich, Germany, as well as by the Olympique Lyonnais, a member of the Union of European Football Associations (UEFA).
Organized in Germany, by Professor Georg Vogel, MD, a well known expert in the field on influenza, and the Health Club of Nymphenburger, the school program is designed to educate students and their families as to the importance of early detection of influenza. As to the objective of the program, Dr. Vogel said, "Schools, like other crowded places, are perfect breeding grounds for the influenza virus. By employing a rapid test, we can isolate and treat students, their family as needed, and thereby prevent the spread of this serious disease." Prof. Vogel is a physician of internal medicine, gastroenterology/nephrology in Munich, Germany and a distinguished expert in Germany in the field of acute respiratory illnesses. Added Mr. Nessler, Diplom teacher for sports at the Nymphenburger Schools, "Prof. Vogel impressed upon us the importance of deploying the QuickVue Influenza test with the main goal of insuring the health and well being of our student population."
Argene, Quidel's French distributor for their rapid diagnostic tests, secured adoption of the QuickVue Influenza A+B test by Olympique Lyonnais, the number one ranked team in the Group F competition in the European League. The test, which provides test results to team physicians in 10 minutes or less, assists in managing possible influenza outbreaks during the season. "We were approached by the team during a sales call to their club headquarters where we were interested in their risk to influenza-like illnesses during the season," said Pascal Margry, Distributions Manager of Argene, which is located in Varilhes, France. "They were enthusiastic to utilize the test because when one player comes down with influenza, there is a likelihood that the rest of the team may be affected as well."
Concern over the overall management of influenza among teams, schools and workgroups has been accentuated this season. "The use of our influenza test in these European venues further validates the QuickVue Influenza A+B test," said Caren Mason, president and CEO of Quidel Corporation. "We are proud of both the Nymphenburger Schools' and Olympique Lyonnais' choice of our test which, combined with the work of Dr. Vogel and other key opinion leaders in France, Japan and the U.S., will continue to educate the worldwide audience as to the critical role testing has in the management of the influenza virus," continued Mason.
About Quidel Corp.
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue, the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration ("FDA"), intellectual property, product liability, environmental or other litigation, and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
SOURCE: Quidel Corporation
Paul Landers, 858-552-1100
Lippert/Heilshorn & Associates
Don Markley/Bruce Voss, 310-691-7100